echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Medical News > Latest Medical News > Luoxin Pharmaceutical and HK inno.N of South Korea join hands again, aiming at the US$2 billion Chinese PPI injection market

    Luoxin Pharmaceutical and HK inno.N of South Korea join hands again, aiming at the US$2 billion Chinese PPI injection market

    • Last Update: 2021-07-29
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com


    Tigolasan is a potassium ion competitive acid blocker (P-CAB).
    Currently, there is no P-CAB injection on the market globally, and Luoxin Pharmaceutical is the first to deploy

    .
      

      P-CAB, as a new type of acid-suppressing drug, makes up for the "pain points" of traditional acid-suppressing drugs PPI, which requires acid activation, short half-life and insufficient acid suppression, resulting in low mucosal healing rate
    .
    Its mechanism of inhibiting acid secretion is to competitively bind to the potassium ion binding site of H+/K+-ATPase (proton pump) in parietal cells

    .
    Unlike Proton Pump Inhibitor (PPI), P-CAB can directly inhibit H+/K+-ATPase without activation in a strong acid environment

    .
    Moreover, whether H+/K+-ATPase is activated or not, P-CAB can bind to it

    .
      

      Tigolasan injection is mainly used for the treatment of gastroesophageal reflux, upper gastrointestinal bleeding and prevention of stress gastric mucosal injury, etc.
    It has fast onset, long action time, stability under acidic conditions, and can simultaneously inhibit activation and resting states Features such as proton pump

    .
      

      According to IQVIA data, China's proton pump inhibitor (PPI) drug market in 2020 will be approximately US$3 billion, ranking second in the world after the United States, of which the injection market size is approximately US$2 billion and approximately RMB 12.
    8 billion, accounting for the PPI drug market 60%

    of In the field of digestive products, Luo Xin's research and products on sale have covered mainstream indications
    .
    This time, together with HK inno.
    N Corporation, we have once again worked together to develop the PPI injection market in China, further consolidating Luo Xin's leading position in the digestion field

    .
    According to the terms of the agreement, Shandong Luoxin will obtain the exclusive development, production and commercialization rights of Tigolasheng injection products in China, and will pay HK inno.
    N Corporation a total of not more than US$5 million in down payment and milestone payments

    .
      

      The cooperation between Luoxin Pharmaceutical and HK inno.
    N Corporation (formerly CJ HealthCare Corporation) can be traced back to 2015.
    The two parties reached an agreement on the exclusive development, production and commercialization rights of Tigola Green Tablets (LXI-15028 project) in China

    .
    It is understood that HK inno.
    N Corporation is a group company that will soon be listed on the Korean Stock Exchange

    .
    Since its establishment in 1984, it has taken the lead in the Korean pharmaceutical market with its prescription drugs such as gastrointestinal drugs and anticancer drugs

    .
    One of the three listed P-CAB drugs in the world is Tegoprazan of HK inno.
    N Corporation in South Korea

    .
    Currently, this product is only marketed in South Korea .
      

      According to IQVIA data, the global sales of ticolax tablets in 2020 will be US$50 million (calculated at the ex-factory price), an increase of 106% year-on-year
    .
    P-CAB oral preparations are only marketed in China with Takeda's Vonolasen tablets, which have been included in the National Medical Insurance List in 2020 through the negotiation of innovative drugs and medical insurance

    .
      

      In June 2017, Luoxin's LXI-15028 project obtained clinical trial approval.
    In 2019, the results of the first phase III clinical study reached the primary efficacy endpoint and were included in the national major science and technology special plan for "Major New Drug Development"

    .
    At present, Luoxin Pharmaceutical has submitted and accepted the application for the listing of a Class 1 new drug Tigola Green Tablets to the National Medical Products Administration

    .
      

      The cooperation between China and South Korea on tegoraxan injection products further demonstrates Luoxin Pharmaceutical's R&D and commercialization advantages in the gastrointestinal field
    .
    After years of accumulation, Luoxin Pharmaceutical has successfully established a market position in core areas such as digestion and breathing, and has reserved a comprehensive and competitive product portfolio

    .
    Adhering to the strategy of "Science and Technology", we will focus on the areas of superiority and continue to consolidate our advantages and improve the competitiveness of our products

    .
    Looking forward to providing new options for acid suppression treatment soon

    .

    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent Echemi's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.